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Abstract: Women carrying a BRCA mutation have an increased risk of developing breast and ovarian
cancer. The most effective strategy to reduce this risk is the bilateral salpingo-oophorectomy, with
or without additional risk-reducing mastectomy. Risk-reducing bilateral salpingo-oophorectomy
(RRBSO) is recommended between age 35 and 40 and between age 40 and 45 years for women
carriers of BRCA1 and BRCA2 mutations, respectively. Consequently, most BRCA mutation carriers
undergo this procedure prior to a natural menopause and develop an anticipated lack of hormones.
This condition has a detrimental impact on various systems, affecting both the quality of life and
longevity; in particular, women carrying BRCA1 mutation, who are likely to have surgery earlier
as compared to BRCA2. Hormonal replacement therapy (HRT) is the only effective strategy able
to significantly compensate the hormonal deprivation and counteract menopausal symptoms, both
in spontaneous and surgical menopause. Although recent evidence suggests that HRT does not
diminish the protective effect of RRBSO in BRCA mutation carriers, concerns regarding the safety of
estrogen and progesterone intake reduce the use in this setting. Furthermore, there is strong data
demonstrating that the use of estrogen alone after RRBSO does not increase the risk of breast cancer
among women with a BRCA1 mutation. The additional progesterone intake, mandatory for the
protection of the endometrium during HRT, warrants further studies. However, when hysterectomy
is performed at the time of RRBSO, the indication of progesterone addition decays and consequently
its potential effect on breast cancer risk. Similarly, in patients conserving the uterus but undergoing
risk-reducing mastectomy, the addition of progesterone should not raise significant concerns for
breast cancer risk anymore. Therefore, BRCA mutation carriers require careful counselling about the
scenarios following their RRBSO, menopausal symptoms or the fear associated with HRT use.
Keywords: bilateral salpingo-oophorectomy; BRCA mutation carriers; breast cancer; hormonal
replacement therapy; menopause; ovarian cancer; risk reducing surgery
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Historically, menopause was considered to be a form of neurosis resulting from the loss of
femininity and until 1980, menopause was included among the criteria defining psychosis in the
Diagnostic and Statistical Manual of Mental Disorders (DSM). The psychoanalytic theory which
underpins this diagnosis relates to that of female sexual development and according to Freud’s theory,
women may face depression at this time which can be explained by the female castration complex.
Nowadays, according to the National Comprehensive Cancer Network (NCCN) guidelines,
risk-reducing bilateral salpingo-oophorectomy (RRBSO) is recommended after completion of
childbearing between age 35 and 40 years for women carriers of BRCA1 mutations and between age
40 and 45 years for women carriers of BRCA2 mutations in order to reduce their risk of developing
breast and ovarian cancer. It is estimated that 65% of women carrying BRCA1 mutation will have
risk-reducing salpingo-oophorectomy prior to their natural menopause [1], experiencing an earlier
onset of surgically induced menopause.
The beneficial effects of an RRBSO include a reduction in ovarian cancer incidence of up to 96%
and in breast cancer incidence up to 50% [2,3]. This translates to a reduction in ovarian cancer-specific
mortality of 95% and in breast cancer-specific mortality of 42% [4]. Interestingly, the risk reduction in
breast cancer-specific mortality is more pronounced for BRCA1 mutated women (HR 0.45, p < 0.0001)
as compared to BRCA2 mutated women for whom the reduction in breast cancer-specific mortality
loses significance (HR 0.88, p = 0.75) [4].
The drawback of such a strikingly effective strategy in reducing the risk to develop a potentially
deadly cancer, such as ovarian cancer is an earlier onset of menopause with subsequent associated
long-term health consequences [5].
In the general population, menopause occurs at a median age of 52 and the onset of menopause at
an age younger or equal to 40 years, in gynecology, is defined as premature ovarian failure.
The lack of hormones that characterizes this status involves various systems and may affect both
quality of life and longevity. Consequently, in women incurring premature ovarian failure, according
to the European Society of Human Reproduction and Embryology (ESHRE) guidelines, hormonal
replacement therapy should be started at the time of diagnosis. This should be continued until the
average age at which the menopause occurs in the general population as a prevention measure against
menopausal symptoms, cardiovascular diseases, osteoporosis, and to reduce the long-term morbidity
associated with the hormone depletion [6].
The most characteristic menopausal symptoms, which result from estrogen deprivation and
affecting more than 80% of women, are the hot flushes, which can significantly impair the quality of
life [7].
Following premature ovarian failure, 43–50% of the women report low sexual desire, over 50%
of the women report vaginal dryness, 17–42% report sexual discomfort and/or pain, and 60% report
difficulties in reaching an orgasm [8]. To relieve these genitourinary symptoms, lubricants and
moisturizers are often prescribed to no avail, whereas the most efficient strategy is a topical treatment
with estrogens (17-beta-estradiol, conjugated equine estrogens, or estriol) [9,10].
In addition to these symptoms, neurological dysfunction, cognitive impairment, and dementia are
reported in several cases [11,12]. Despite the lack of strong data supporting the benefits of hormonal
replacement therapy on memory and communication, ESHRE guidelines recommend the adoption of
hormonal replacement therapy in women with premature ovarian failure to reduce the risk of cognitive
impairment [6]. With regards to mood disorders including depressive symptoms, there is evidence
suggesting the beneficial effects of a hormonal replacement therapy [13].
Given the crucial role played by the estrogens in the metabolism of the bones, it is clear that the
early onset of menopause has detrimental effects on the bone density and bone structure leading to an
increased risk of bone fracture [5,14]. The negative effect of early-onset menopause on bone mineral
density reduction has been recorded in the lumbar spine and femur [15]. It has been demonstrated
that hormonal replacement therapy can protect against osteopenia and osteoporosis and can restore
bone density in women with premature ovarian failure [16]. The protective effect appears to be higher
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in women who have undergone hormonal replacement therapy for at least five years and is optimized
when a combination of transdermal estradiol and vaginal progesterone are used [17].
Finally, the lack of estrogens in women with premature ovarian failure leads to a modification of the
lipid profile that leads to endothelial dysfunction with an increased risk of early cardiovascular-related
mortality [16,18]. When a hormonal replacement therapy is initiated, the endothelial function can
be restored within six months [19]. As such, ESHRE recommends hormonal replacement therapy in
women with premature ovarian failure to reduce the risk of cardiovascular disease [6]. Hormonal
treatment should always be accompanied with advice on optimizing lifestyle factors, including regular
physical activity, a balanced diet, and a cessation of nicotine [6].
Although hormone replacement in women with premature ovarian failure may occur via combined
oral contraceptives or via conventional hormonal replacement therapy, the latter method more closely
mimics the physiological concentrations of both estrogen and progesterone [18].
Estrogens can be administered orally, transdermally, or topically. The preferred route of
administration is the transdermal as it guarantees a systematic distribution of the hormone and
is not associated with an increased risk of cardiovascular morbidity linked to the oral administration
of the estrogens. The risk of endometrial cancer is 4.5 times greater among women exposed to estrogen
therapy without combined progesterone therapy [20]. The systemic administration of estrogens has to
be balanced by a course of progestins for at least 10 days per month to prevent endometrial hyperplasia
and cancer [21].
Progestins can be administered orally, vaginally, or via a medicated intrauterine device. At present,
it is unclear whether the administration of progestins via subcutaneous implants and intramuscular
injections imparts sufficient endometrial protection during hormonal replacement therapy. Among the
various progestins, it seems that micronized progesterone has a greater cardiovascular protective effect
and may reduce the risk of breast cancer risk as compared with other progestins [6]. Although several
studies have demonstrated that micronized progesterone confers adequate endometrial protection,
some authors still question its efficacy [13,22]. With regards to side effects, micronized progesterone
and the most commonly used progestin, medroxyprogesterone acetate, are associated with an increased
risk of thrombosis when adopted in hormonal replacement therapy [23].
Despite ESHRE recommendations and the apparent benefits of hormone replacement therapy,
approximately 40% of women with premature ovarian failure discontinue treatment within one
year [17,24].
Two of the largest studies of HRT raised concerns regarding the safety of HRT in general population,
in terms of risk of breast cancer and heart disease [25,26]. The results of these studies received wide
publicity, generating panic and restrictions from several regulatory authorities. However, these studies
were biased since women included in the studies were mostly in their mid-sixties, often overweight,
and thus unrepresentative of women for whom HRT should be considered suitable. Unfortunately,
this about turn and retraction of some of the previous findings has received smaller emphasis from the
media, therefore, facilitating the persistence of misconceptions.
Based on the available evidence, which constitutes mostly on retrospective studies, the short-term
use of HRT does not have any influence on the protective effect of the RRBSO on breast cancer
incidence [1,27,28]. Women who are mutation carriers of BRCA 1 and BRCA2 genes may have different
levels of cancer risk based on the differences of breast cancer subtypes they typically develop.
For BRCA1 mutation carriers, the use of HRT after RRBSO did not increase the incidence of
breast cancer in a large prospective study [1]. On the contrary, an estrogen-only HRT may even have a
protective effect against breast cancer. Although these figures did not reach statistical significance,
Kostopoulos et al. recorded an 8% reduction in breast cancer risk (HR, 0.92; 95% CI, 0.83–1.01) for
every year of estrogen replacement and an 8% increase in breast cancer risk (HR,1.08; 95% CI, 0.92–1.27)
for every year of progestin replacement. In this study, the 10-year actuarial risk of breast cancer
differed significantly between women using estrogen-only and combined estrogen and progestin
replacement therapy (12% vs. 22%; absolute difference, 10%; p = 0.04) and was particularly striking
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for women undergoing RRBSO prior to 45 years of age (9% vs. 24%; p = 0.009). In this subgroup of
women who underwent RRBSO prior to age 45, the protective effect on breast cancer risk conferred
by an estrogen-only hormonal replacement therapy reached statistical significance with an 18% risk
reduction (95% CI, 0.69–0.97) per year of treatment. In the same subgroup of women, a non-significant
increase in breast cancer risk of 14% (95% CI, 0.90–1.46) was calculated for every year of combined
estrogen-progestin replacement therapy. These findings are consistent with those reported in large
prospective studies and randomized clinical trials performed in women who do not carry mutations of
the BRCA genes [26,29–32].
The potential negative effect of the progestins on breast cancer risk may be explained by the
role of the progesterone/receptor activator of nuclear factor-kB (RANK)-signaling pathway in BRCA
1 breast cancer development [33,34]. Although the molecular mediators and hormones associated
with BRCA 1 and 2 mutations have not been clearly identified, progesterone clearly played a role
in mammary tumorigenesis of BRCA 1/p53 in a murine model [35]. RANKL/RANK has also been
found to be associated with progestin-driven mammary cancer in mouse models and may have a role
in the etiology of BRCA1/2 mutation-driven breast cancer. Progesterone stimulates the secretion of
RANKL/RANK by estrogen receptor (ER) and progesterone receptor (PR)-positive mammary epithelial
cells, which in turn acts on ER/PR-negative epithelial progenitor cells, promoting proliferation and
expansion of mammary epithelial cells. In BRCA1/2 carriers with triple-negative breast cancer, RANK
has been implicated for the signaling on progenitor cells, which are believed to be “seed cells” and
BRCA1 regulates the development of the human mammary stem and progenitor cell [35].
For BRCA 2 mutation carriers, available data on the use of HRT are less available. In these
patients, the adoption of an HRT is probably less important given the later age at which they typically
undergo an RRBSO and given their propensity to develop hormone receptor-positive breast cancers.
Hence, HRT in this subset of patients should be adopted with caution.
In conclusion, the adoption of an estrogen-only hormonal replacement therapy after RRBSO does
not increase the risk of breast cancer among women with a BRCA 1 mutation and should reassure
BRCA1 mutation carriers considering risk-reducing surgery that HRT is safe. The potential adverse
effect of progestin containing HRT warrants further studies. Similarly, studies should investigate
whether route, regimen or dose of HRT differentially impacts breast cancer risk as well as the impact
of intrauterine devices as HRT. The risk associated with progestins may be of little clinical impact in
women undergoing both RRBSO and risk-reducing mastectomy. For women who select not to undergo
a mastectomy, the use of progestins may be avoided in cases of previous hysterectomy or when a
hysterectomy is performed in conjunction with the RRBSO.
Although the morbidity of a hysterectomy and bilateral salpingo-oophorectomy is somewhat
higher than that of a bilateral salpingo-oophorectomy, women undergoing RRBSO, especially if aged
under 45 years, should be counseled that the removal of the uterus will eradicate the need for progestins.
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